Roth just rated IMU a buy, page-66

Re perceived discrepancy between PFS and OS time frames in Roth Report and Clinicaltrials.gov re Hervaxx, I received an email response from the same email address I used to contact the Roth Report writer. The response is as follows:

”You are talking about how long it takes each individual patient to progress or die, on average. I am talking about when enough patients experience that so that they can release the data. They are two very different things.”

I can’t say that I fully understand that, but in relation to the Phase 1 results and the “beautiful numbers”, it infers that not enough patients have progressed or died such that data can be released. Leslie did say something similar.

I just don’t understand how Roth can put a time estimate on it.

In any event, I am confident great things will be achieved well before then.

Go Imugene.

PDS